Serum neopterin and TNF-α levels in psoriasis and their correlation with disease severity;Psoriasisde serum neopterin ve TNF-α düzeyleri ve hastalik şiddeti ile i̇lişkisi

Turkderm Deri Hastaliklari ve Frengi Arsivi

Volumn 46, Issue 1, 2012, Pages 7-10

  Ceyhan, Ali Murat ^a   Yildirim, Mehmet ^a   Ceyhan, Betül Mermi ^b   Sütçü, Recep ^b  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Tibbi Biyokimya Anabilim Dali   (Turkey)

Author keywords

Neopterin; Psoriasis; TNF

Indexed keywords

NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PSORIASIS; PSORIASIS SEVERITY INDEX; STATISTICAL SIGNIFICANCE;

EID: 84859630765     PISSN: 1019214X     EISSN: None     Source Type: Journal    
DOI: 10.4274/turkderm.60243     Document Type: Article

References (26)

1. Das RP, Jain AK, Ramesh V: Current concepts in the pathogenesis of psoriasis. Indian J Dermatol 2009;54:7-12.
2. Erkek E: Psoriasis patogenezinde yenilikler. T Klin J Dermatol 2008;1:1-14.
3. Mehlis SL, Gordon KB: The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003;49:44-50.
4. Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol 1999;135:1104-10.
5. Berdowska A, Zwirska- Korczala K: Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001:319-29. (Pubitemid 32989554)
6. Wachter H, Hausen A, Grassmayr K: İncreased urinary excretion of neopterin in patients with malignant tumors and with virus diseases. Hoppe Seylers Z Physiol Chem 1979;360:1957-60. (Pubitemid 10180477)
7. Fuchs D, Weiss G, Watcher H: Neopterin, biochemistry and clinical use as a marker celluler immune reactions. Int Arc All Immunol 1993;101:1-6. (Pubitemid 23179069)
8. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER: Neopterin as a marker of celluler immunity: Immunologic basis and clinical application. Adv Clin Chem 1989; 27:81-141.
9. Koc E, Tunca M, Akgul EO, et al: Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study. J Dermatol 2009;36:191-6.
10. Adişen E, Gürer MA: Psoriasis, genel bilgiler, epidemiyoloji. Türkderm 2008;42:15-7.
11. Davidovici BB, Sattar N, Prinz JC, et al: Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;13:1785-96.
12. Arican O, Aral M, Şazmaz S, et al: Serum levels of TNF-alpha, IFN-gamma, IL-6, IL8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005;5:273-9. (Pubitemid 41577417)
13. Borská L, Fiala Z, Krejsek J, et al: Selected immunological changes in patients with Goeckerman's therapy TNF-alpha, sE-selectin, sP-selectin, sICAM-1 and IL-8. Physiol Res 2006;55:699-706. (Pubitemid 46021230)
14. Mussi A, Bonifati C, Carducci M, et al: Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997;11:115-8. (Pubitemid 28045966)
15. Bozkurt NM, Yildirim M, Ceyhan AM, Kara Y, Vural Y: Psoriasisli hastalarda serum visfatin düzeylerinin araştirilmasi. Türkderm 2010;44:15-8.
16. Gönül T, Başak PY, Kara Y Akaya VB, Vural H: Psoriasisli hastalarda serum leptin düzeylerinin araştirilmasi. Türkderm 2009;43:48-52.
17. Ragab HM, El Maksoud NA, Farid Roaiah MM: Biochemical Significance of Proinflammatory Cytokines in Psoriasis vulgaris among Egyptian Patients. J Am Sci 2010;6:423-9.
18. Chodorowska G: Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment. J Eur Acad Dermatol Venereol 1998;10:147-51.
19. Tigalonova M, Bjerke JR, Gallati H, et al: Serum levels of interferons and TNF-alpha are not correlated to psoriasis activity and therapy. Acta Derm Venereol 1994;186:25-7. (Pubitemid 24208143)
20. Erturan I, Basak PY, Ozturk O, Ceyhan AM, Akkaya VB: Is there any relationship between serum and urine neopterin and serum interferon-gamma levels in the activity of Behcet's disease? J Eur Acad Dermatol Venereol 2009;231:1414-8.
21. Hoffmann G, Wirleitner B, Fuchs D: Potential role of immun system activation-assciated production of neopterin dervatives in humans. İnflamm Ress 2003;52:313-321,
22. Sanchez-Regana M. Catasus M, Creus L, Umbert P: Serum neopterin as an objective marker of psoriatic disease activity. Acta Derm Venereol 2000;80:185-7.
23. Harland CC, Whitaker RP, Baron JL, Holden CA: Increased urine neopterin levels in psoriasis. Br J Dermatol 1992;127:453-7.
24. Fuchs D, Sepp N, Susanne B, Fritsch P, Watcher H: Immune activation and psoriasis. Lancet 1991;338:759.
25. De Rie MA, Hamerlinck F, Bos JD: Neopterin, immun activation, and psoriasis. Lancet 1991;338:1208.
26. Okubo Y, Irisawa R, Koga M: Neopterin in serum from patient with psoriasis. J Dermatol Scie 1996;12:186.